Navigation Links
GlycoFi and Dartmouth report full humanization of yeast glycosylation pathway in Science

For the first time, scientists have engineered yeast cells capable of producing a broad repertoire of recombinant therapeutic proteins with fully human sugar structures (glycosylation). These sugar structures ensure a glycoprotein's biological activity and half-life and to date, have necessitated the expression of therapeutic glycoproteins in mammalian hosts. The accomplishment reported today has the potential to eliminate the need for mammalian cell culture, while improving control over glycosylation, and improving performance characteristics of many therapeutic proteins.

Scientists from GlycoFi, Inc., a wholly owned subsidiary of Merck & Co., Inc., and their collaborators at Dartmouth-Hitchcock Medical Center published their report detailing the genetic engineering of the yeast Pichia pastoris to secrete human glycoproteins with fully complex, terminally sialyated N-glycans today in the September 8, 2006 issue of the journal Science. To demonstrate the utility of the engineered yeast strains, recombinant erythropoietin (Epo), a protein that stimulates the production of red blood cells, was expressed, purified and its activity demonstrated in vivo.

"Re-engineering the yeast glycosylation system to fully replicate the full repertoire of human glycosylation reactions has been a challenging six year effort that many doubted could be accomplished," said Tillman Gerngross, Ph.D., chief scientific officer of GlycoFi and professor of Bioengineering at Dartmouth College.

"This achievement required both the elimination of yeast-specific glycosylation reactions and the introduction of 14 heterologous genes, making this one of the most complex cellular engineering endeavors reported to date", said Stephen Hamilton, Ph.D., the lead author of the study and a senior scientist at GlycoFi.

Yeast offers numerous advantages as a recombinant protein expression system when compared to mammalian cell culture. These include the capability of producing higher recombinant protein titers, shorter fermentation times, and the ability to grow in chemically defined media, without risk of viral contamination from animal-derived ingredients.

"Switching to this technology will also provide improvements in product uniformity and overall production economics," Dr. Gerngross said. He noted that the GlycoFi and Dartmouth research team had previously published work showing how a panel of glyco-engineered yeast cell lines, displaying a more limited repertoire of human glycosylation reactions, had allowed the scientists to study the relationship between specific glycosylation structures on antibodies and their killing activity on cancer cells. Using this technology, the team had identified glycosylation structures that significantly improved an antibodies ability to kill cancer cells compared to the same antibody manufactured using mammalian cell culture.

"By engineering yeast to perform the final and, most complex step of human glycosylation, we are now able to conduct far more extensive structure-function investigations on a much wider range of therapeutic protein targets," Dr. Gerngross commented.
'"/>

Source:JKureczka@comcast.net


Related biology news :

1. GlycoFi announces the first production of antibodies with human glycosylation in yeast
2. Dartmouth study finds that arsenic inhibits DNA repair
3. Octopuses occasionally stroll around on two arms, UC Berkeley biologists report
4. Surprising findings reported about iron overload
5. Researchers report new pro-inflammatory role for anti-inflammatory enzyme
6. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
7. Leprosy genome tells story of human migrations, French researchers report in Science
8. Novel live reporting system to track cells
9. Biased reporting found in cancer prognostic studies
10. New lead reported in tumor angiogenesis
11. Researchers report breakthrough against world’s deadliest viruses

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: